Clostridioides difficile infection (CDI) can lead to severe diarrhea, pseudomembranous colitis, and potentially life-threatening intestinal complications. Current treatments rely primarily on antibiotics; however, recurrence rates remain high at 20–30%. Moreover, prolonged antibiotic use can disrupt the balance of the gut microbiota, making patients more susceptible to reinfection.
To address the challenges in CDI treatment, Associate Professor Wei-Hsuan Hsu of National Cheng Kung University and Assistant Professor Lee, Bao-Hong of National Chiayi University have developed an innovative probiotic-derived extracellular vesicle (EV) technology. This approach utilizes extracellular vesicles secreted by specific probiotic strains as natural nanocarriers to deliver small RNA fragments directly into pathogenic bacteria. These RNAs inhibit the expression of toxin genes, effectively suppressing the growth of Clostridioides difficile without disturbing the normal gut microbiota.
Probiotic Extracellular Vesicles: Precision Targeting to Restore Gut Microbiota Balance
Associate Professor Wei-Hsuan Hsu’s team established a biomimetic gut dynamic system using tandem bioreactors to successfully cultivate a complex gut microbial ecosystem. They innovatively applied probiotic-derived EVs for the treatment of CDI. Thanks to their double-membrane structure, the EVs efficiently penetrate pathogenic bacteria. Through specific lipid recognition mechanisms, they selectively enter Clostridioides difficile cells and deliver their cargo with precision. Once inside, the small RNA fragments encapsulated within the vesicles are released, employing RNA interference (RNAi) to accurately suppress bacterial proliferation and toxin expression.
Animal studies have demonstrated that oral administration of these probiotic-derived EVs significantly reduces the load of Clostridioides difficile in mice, effectively alleviating infection-induced diarrhea and intestinal inflammation. Compared with conventional antibiotic treatments, this method not only lowers recurrence rates but also maintains gut microbiome balance, thereby avoiding health risks associated with dysbiosis. Additionally, these EVs can be directly extracted from probiotic fermentation broth without the need for additional production processes, offering advantages of low cost, high yield, and alignment with environmentally sustainable principles.
Diverse Applications and Promising Prospects in Precision Medicine
As global attention on gut microbiome therapies grows, probiotic-derived extracellular vesicle technology offers an innovative solution for CDI treatment and demonstrates vast potential in the fields of precision medicine and biopharmaceuticals. According to Associate Professor Wei-Hsuan Hsu, the technology has already completed preclinical functional validation, patent filings, and commercial technology transfers. Plans are underway to initiate human clinical trials and advance the technology toward market entry.
Furthermore, the research team has established a comprehensive database of probiotic-derived extracellular vesicles, confirming that EVs secreted by different probiotic strains can target specific organs. In the future, this platform technology could be expanded beyond gut-related diseases to precision therapies for the liver, lungs, and nervous system, providing patients with safer and more effective treatment options.
Resource: 創新益生菌胞外泌體技術 抑制艱難梭狀芽孢桿菌毒素感染
